Combining radiation and cancer gene therapy: A potential marriage of physical and biological targeting?

Current Cancer Drug Targets

Volumn 7, Issue 4, 2007, Pages 389-409

  Hingorani, M ^a   White, C L ^a   Agrawal, V K ^a   Vidal, L ^a   Melcher, A ^b   Harrington, K J ^a,c  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^c IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

Cancer; Gene therapy; Radiation; Radiosensitivity

Indexed keywords

1 AZIRIDINO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL; ADENOVIRUS VECTOR; ADVEXIN; ANGIOSTATIN; CV 706; CV 787; CYTOSINE DEAMINASE; EARLY GROWTH RESPONSE FACTOR 1; ENDOSTATIN; FAS LIGAND; FLUCYTOSINE; GANCICLOVIR; GENE PRODUCT; IODINE 131; METAIODOBENZYL GUANIDINE I 131; METAIODOBENZYL GUANIDINE I 211; N (4 METHOXYPHENYLACETYL)DEHYDROALANINE; ONCOLYTIC ADENOVIRUS; ONYX 015; PROTEIN P53; RADIOPHARMACEUTICAL AGENT; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; THYMIDINE KINASE; TNFERADE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; VALACICLOVIR;

ABSENCE OF SIDE EFFECTS; ANGIOGENESIS; APOPTOSIS; BONE MARROW SUPPRESSION; BRAIN CANCER; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GENE THERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; COLORECTAL CANCER; COMPUTER ASSISTED RADIOTHERAPY; CYTOTOXICITY; DNA REPAIR; DRUG DOSE ESCALATION; DRUG WITHDRAWAL; FEVER; FLU LIKE SYNDROME; GENE DIRECTED ENZYME PRODRUG THERAPY; HEAD AND NECK CANCER; HUMAN; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; INFECTION; INTENSITY MODULATED RADIATION THERAPY; LUNG CANCER; NEUROBLASTOMA; NONHUMAN; ONCOLYTIC VIROTHERAPY; OVARY CANCER; PAIN; PNEUMOTHORAX; PROSTATE ADENOCARCINOMA; RADIOSENSITIVITY; REVIEW; SIDE EFFECT; SUICIDE GENE THERAPY; THYROID CANCER; TUMOR CELL; TUMOR VASCULARIZATION; UNSPECIFIED SIDE EFFECT;

COMBINED MODALITY THERAPY; GENE THERAPY; HUMANS; NEOPLASMS;

EID: 34249817885     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800907780809787     Document Type: Review

References (270)

1. Hanahan, D.; Weinberg, R. A. The hallmarks of Cancer. Cell 2000, 100, 57-70.
2. Vogelstein, B.; Fearon, E. R.; Hamilton, S. R. Genetic alterations during colorectal tumour development. N. Engl. J. Med. 1988, 319, 525-532.
3. Kaye, S. B. Mutidrug resistance: clinical relevance in solid tumours and strategies for circumvention. Curr. Opin. Oncol. 1998, 10, S15-S19.
4. Lane, D. P. Cancerp53, guardian of the genome. Nature 1992, 358, 15-16.
5. Pollack, A.; Zagars, G. K. External beam radiotherapy dose response of prostate Cancer. Int. J. Radiat. Oncol. Biol. Phys. 1997, 39(5), 1011-1018.
6. Pollack, A.; Smith, L. G.; von Eschenbach, A. C. External beam radiotherapy dose response characteristics of 1127 men with prostate cancer treated in the PSA era. Int. J Radiat. Oncol. Biol. Phys. 2000, 48(2), 507-512.
7. Hanks, G. E.; Hanlon, A. L.; Pinover, W. H.; Horwitz, E. M.; Price, R. A.; Schultheiss, T. Dose selection for prostate cancer patients based on dose comparison and dose response studies. Int. J. Radiat. Oncol. Biol. Phys. 2000, 46(4), 823-832.
8. Hanks, G. E.; Hanlon, A. L.; Schultheiss, T. E.; Pinover, W. H.; Movsas, B.; Epstein, B. E.; Hunt.; M. A. Dose escalation with 3D conformal treatment: five year outcomes, treatment optimization, and future directions. Int. J. Radiat. Oncol. Biol. Phys. 1998, 41(3), 501-510.
9. Mendenhall, W. M.; Amdur, R. J.; Palta, J. R. Intensity-modulated radiotherapy in the standard management of head and neck cancer: promises and pitfalls. J. Clin. Oncol. 2006, 24(17), 2618-2623.
10. Zelefsky, M. J.; Fuks, Z.; Hunt M.; Yamada, Y.; Marion, C.; Ling, C. C.; Amols, H.; Venkatraman, E. S, Leibel, S. A. High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. Int. J. Radiat. Oncol. Biol. Phys. 2002, 53(5), 1111-1116.
11. Freytag, S. O.; Kim, J. H..; Brown, S. L, Barton, K.; Lu, M. Gene therapy strategies to enhance the effectiveness of radiotherapy. Curr. Opin. Mol. Ther. 2004, 6(5), 513-524.
12. Peng, K. W.; Vile, R. G. Vector development for cancer gene therapy. Tum. Targeting 1999, 77, 824- 833.
13. Liu, X. Y. Targeting gene-virotherapy of cancer and its prosperity. Cell. Res. 2006, 16(11), 879-886.
14. Kaminski, J. M.; Kaminski, R. J.; Dicker, A. P.; Urbain, J. L. Defining a future role for radiogenic therapy. Cancer Treat Res. 2001, 27(5), 289-294.
15. Kaminski, J. M.; Nguyen, K.; Buyyounouski, M.; Pollack, A. Prostate cancer gene therapy and the role of radiation. Cancer Treat. Rev. 2002, 28(1), 49-64.
16. Palmer, D. H.; Chen, M. J.; Kerr, D. J. Taking Gene Therapy into the Clinic. J. Biomed. Biotechnol. 2003, 1, 71-77.
17. The, B. S.; Aguilar-Cordova, E.; Vlachaki, M. T.; Aguilar, L.; Mai, W. Y.; Caillouet, J. Combining radiotherapy with gene therapy (from the bench to the bedside): a novel treatment strategy for prostate Cancer Oncologist 2002, 7(5), 458-466.
18. Advani, S. J.; Mezhir, J. J.; Roizman, B.; Weichselbaum, R. R. ReVOLT: radiation-enhanced viral oncolytic therapy. Int. J. Radiat. Oncol. Biol. Phys. 2006, 66(3), 637-646.
19. Relph, K.; Harrington, K.; Pandha, H. Recent developments and current status of gene therapy using viral vectors in the United Kingdom. Br. Med. J. 2004, 329, 839-842.
20. Bischoff, J. R.; Kirn, D. H.; Williams, A.; Heise, C.; Horn, S.; Muna, M.; Ng, L.; Nye, J. A.; Sampson-Johannes, A.; Fattaey, A.; McCormick, F. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996, 274, 373-376.
21. Heise, C.; Sampson-Johannes, A.; Williams, A.; McCormick, F.; Von Hoff, D. D.; Kirn, D. H. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat. Med. 1997, 3, 639-645.
22. Rodriguez, R.; Schuur, E. R.; Lim, H. Y.; Henderson, G. A.; Simons, J. W.; Henderson, D. R. Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res. 1997, 57, 2559-2563.
23. Ring, C. J. Cytolytic viruses as potential anti-cancer agents. J. Gen. Virol. 2002, 83, 491-502.
24. Freytag, S. O.; Rogulski, K. R.; Paielli, D. L.; Gilbert, J. D.; Kim, J. H. A novel three-pronged approach to kill cancer cells selectively: concomitant viral, double suicide gene, and radiotherapy. Hum. Gene. Ther. 1998, 9, 1323-1333.
25. Barton, K. N.; Tyson, D.; Stricker, H.; Lew, Y. S.; Heisey, G.; Koul, S.; de la Zerda, A.; Yin, F. F.; Yan, H.; Nagaraja, T. N.; Randall, K. A.; Jin, G. K.; Fenstermacher, J. D.; Jhiang, S.; Ho Kim, J.; Freytag, S. O.; Brown, S L. GENIS: gene expression of sodium iodide symporter for noninvasive imaging of gene therapy vectors and quantification of gene expression in vivo. Mol. Ther. 2003, 8, 508-518.
26. Ganly, I.; Kirn, D.; Eckhardt, G.; Rodriguez, G. I.; Soutar, D. S.; Otto, R.; Robertson, A. G.; Park, O.; Gulley, M. L.; Heise, C.; Von Hoff, D. D.; Kaye, S. B. A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck Cancer Clin. Cancer Res. 2000, 6, 798-806.
27. Hawkins, L. K.; Lemoine, N. R.; Kirn, D. Oncolytic biotherapy:a novel therapeutic platform. Lancet Oncol. 2002, 3, 17-26.
28. Roberts, M. S.; Lorence, R. M.; Groene, W. S.; Bamat, M. K. Naturally oncolytic viruses. Curr. Opin. Mol. Ther. 2006, 8(4), 314-321.
29. Kocahnek, S. High capacity adenoviral vectors for gene transfer and somatic gene therapy. Hum. Gene Ther. 1999, 10, 2451-2459.
30. Zhang, W. W. Development and application of adenoviral vectors for gene therapy of Cancer. Cancer Gene Ther. 1999, 6, 113-138.
31. Lehmann, S. Virus treatment questioned after gene therapy death. Nature 1999, 40, 517-518.
32. Curiel, D. T. The development of conditionally replicative adenoviruses for cancer therapy. Clin. Cancer Res. 2000, 6, 3395-3399.
33. Bischoff, J. R.; Kirn, D. H.; Williams, A. An adenovirus mutant that replicates selectively in p53 deficient human tumour cells. Science 1996, 274, 373-376.
34. Shinoura, N.; Yoshida, Y.; Tsunoda, R.; Ohashi, M.; Zhang, W.; Asai, A.; Kirino, T.; Hamada, H. Highly augmented cytopathic effect of a fiber-mutant E1B-defective adenovirus for gene therapy of gliomas. Cancer Res. 1999, 59, 3411-3416.
35. Yu, D. C.; Sakamoto, G. T.; Henderson, D. R. Identification of the transcriptional regulatory sequences of human kallikrein 2 and their use in the construction of calydon virus 764, an attenuated replication competent adenovirus for prostate cancer therapy. Cancer Res. 1999, 59, 1498-1504.
36. Yu, D.C.; Chen, Y.; Seng, M.; Dilley, J.; Henderson, D. R. The addition of adenovirus type 5 region E3 enables calydon virus 787 to eliminate distant prostate tumor xenografts. Cancer Res. 1999, 59, 4200-4203.
37. Ghosh, S. S.; Gopinath, P.; Ramesh, A. Adenoviral vectors: a promising tool for gene therapy. Appl. Biochem. Biotechnol. 2006, 133(1), 9-29.
38. Miller, A. D. Retroviral vectors. Curr. Top. Microbiol. Immunol. 1992, 158, 1-24.
39. Hacein-Bey-Abina, S.; Von Kalle, C.; Schmidt, M. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N. Engl. J. Med. 2003, 348, 255-256.
40. Hacein-Bey-Abina, S.; Von Kalle, C.; Schmidt M. et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003, 302, 415-419.
41. Naldini, L.; Blomer, U.; Gallay, P.; Ory, D.; Mulligan, R.; Gage, F. H.; Verma, I. M.; Trono, D. In vivo gene delivery and stable transduction of nondividing cells by lentiviral vector. Science 1996, 272, 263-267.
42. Yoon, S. S.; Nakamura, H.; Carroll, N. M.; Bode, B. P.; Chiocca, E. A.; Tanabe, K. K. An oncolytic herpes simplex virus type 1 selectively destroys diffuse liver metastases from colon carcinoma. FASEB J. 2000, 14, 301-311.
43. Smith, E. R.; Chiocca, E. A. Oncolytic viruses as novel anticancer agents: turning one scourge against another. Exp. Opin. Investig. Drugs 2000, 9, 311-327.
44. Rampling, R.; Cruickshank, G.; Papanastassiou, V.; Nicoll, J.; Hadley, D.; Brennan, D.; Petty, R.; MacLean, A.; Harland, J.; McKie, E.; Mabbs, R.; Brown, M. Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene. Ther. 2000, 7, 859-866.
45. Hunter, W. D.; Martuza, R. L.; Feigenbaum, F.; Todo, T.; Mineta, T.; Yazaki, T.; Toda, M.; Newsome, J. T.; Platenberg, R. C.; Manz, H. J.; Rabkin, S. D. Attenuated, replication-competent herpes simplex virus type 1 mutant G207: safety evaluation of intracerebral injection in nonhuman primates. J. Virol. 1999, 73, 6319-6326.
46. Mineta, T.; Rabkin, S. D.; Yazaki, T.; Hunter, W. D.; Martuza, R. L. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat. Med. 1995, 1, 938-943.
47. Rey, F. A. Molecular gymnastics at the herpesvirus surface. EMBO Rep. 2006, 7(10), 1000-1005.
48. Flotte, T. R.; Carter, B. J. Adeno-associated viral vectors. In: Meager A.; ed. Gen. therapy Technologies, Applications And Regulations. Wiley: Chichester, UK, 1999.
49. Mastrangelo, M. J.; Maguire, H. C. Jr.; Eisenlohr, L. C.; Laughlin, C. E.; Monken, C. E.; McCue, P. A.; Kovatich, A. J.; Lattime, E. C. Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma. Cancer Gene Ther. 1999, 6, 409-422.
50. Pantuck, A. J.; van Ophoven, A.; Gitlitz, B. J.; Tso, C. L.; Acres, B.; Squiban, P.; Ross, M. E.; Belldegrun, A. S.; Figlin, R. A. Phase I trial of antigen-specific gene therapy using a recombinant vaccinia virus encoding MUC-1 and IL-2 in MUC-1-positive patients with advanced prostate Cancer J. Immunother. 2004, 27, 240-253.
51. Wallack, M. K.; Scoggin, S. D.; Sivanandham, M. Active specific immunotherapy with vaccinia melanoma oncolysate. Mt. Sinai. J. Med. 1992, 59, 227-233.
52. Wallack, M. K.; Sivanandham, M.; Balch, C. M.; Urist, M. M.; Bland, K. I.; Murray, D.; Robinson, W. A.; Flaherty, L.; Richards, J. M.; Bartolucci, A. A.; Rosen, L. Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: the final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial. J. Am. Coll. Surg. 1998, 187, 69-79.
53. Orynbayeva, Z.; Kolusheva, S.; Groysman, N.; Gavrielov, N.; Lobel. L.; Jelinek. R. Vaccinia virus interactions with the cell membrane studied by new chromatic vesicle and cell sensor assays. J. Virol. 2007, 81, 1140-1147.
54. Harrington, K. J.; Linardakis, E.; Vile, R. G. Transcriptional control: an essential component of cancer gene therapy strategies? Adv. Drug Deliv. Rev. 2000, 44, 167-184.
55. Gu, J.; Kagawa, S.; Takakura, M.; Kyo, S.; Inoue, M.; Roth, J. A.; Fang, B. Tumor-specific transgene expression from the human telomerase reverse transcriptase promoter enables targeting of the therapeutic effects of the Bax gene to cancers. Cancer Res. 2000, 60, 5359-5364.
56. Koga, S.; Hirohata, S.; Kondo, Y.; Komata, T.; Takakura, M.; Inoue, M.; Kyo, S.; Kondo, S. A novel telomerase-specific gene therapy: gene transfer of caspase-8 utilizing the human telomerase catalytic subunit gene promoter. Hum. Gene Ther. 2000, 11, 1397-1406.
57. Lin, C. S.; Chen, Z. P.; Park, T.; Ghosh, K.; Leavitt, J. Laboratory of Cancer Cell Biology, Palo Alto Medical Foundation Research Institute, California 94301. J. Biol. Chem. 1993, 268, 2793-2801.
58. Chung, I.; Schwartz, P. E.; Crystal. R. G.; Pizzorno, G.; Leavitt, J.; Deisseroth, A. B. Use of L-plastin promoter to develop an adenoviral system that confers transgene expression in ovarian cancer cells but not in normal mesothelial cells. Cancer Gene Ther. 1999, 6, 99-106.
59. Katabi, M. M.; Chan, H. L.; Karp, S. E.; Batist, G. Hexokinase type II: a novel tumor-specific promoter for gene-targeted therapy differentially expressed and regulated in human cancer cells. Hum. Gene Ther. 1999, 10, 155-164.
60. Gossen, M.; Freundlieb, S.; Bender, G.; Muller, G.; Hillen, W.; Bujard, H. Transcriptional activation by tetracyclines in mammalian cells. Science 1995, 268, 766-769.
61. Burcin, M. M.; Schiedner, G.; Kochanek, S.; Tsai, S. Y.; O'Malley, B. W. Adenovirus-mediated regulable target gene expression in vivo. Proc. Natl. Acad. Sci. USA 1999, 96, 355-360.
62. Gerner, E. W.; Hersh, E. M. Heat inducible vectors for use in gene therapy. Int. J. Hyperthermia 2000, 16, 171-181.
63. Vekris, A.; Maurange, C.; Moonen, C.; Mazurier, F.; De Verneuil, H.; Canioni, P.;Voisin, P. Control of transgene expression using local hyperthermia in combination with a heat-sensitive promoter. J. Gene Med. 2000, 2, 89-96.
64. Dachs, G. U.; Patterson, A. V.; Firth, J. D.; Ratcliffe, P. J.; Townsend, K. M.; Stratford, I. J.; Harris, A. L. Targeting gene expression to hypoxic tumor cells. Nat. Med. 1997, 3, 515-520.
65. Koshikawa, N.; Takenaga, K.; Tagawa, M.; Sakiyama, S. Therapeutic efficacy of the suicide gene driven by the promoter of vascular endothelial growth factor gene against hypoxic tumor cells. Cancer Res. 2000, 60, 2936-2941.
66. Jaggar, R. T.; Chan, H. Y.; Harris, A. L.; Bicknell, R. Endothelial cellspecific expression of tumor necrosis factor-alpha from the KDR or E-selectin promoters following retroviral delivery. Hum. Gene Ther. 1997, 8, 2239-2247.
67. Walton, T.; Wang, J. L.; Ribas, A.; Barsky, S. H.; Economou, J.; Nguyen, M. Endothelium-specific expression of an E-selectin promoter recombinant adenoviral vector. Anticancer Res. 1998, 18 (3A), 1357-1360.
68. Graulich, W.; Nettelbeck, D. M.; Fischer, D.; Kissel, T.; Muller, R. Cell type specificity of the human endoglin promoter. Gene 1999, 227, 55-62.
69. Rasmussen, H.; Rasmussen, C.; Lempicki, M.; Durham, R.; Brough, D.; King, C. R.; Weichselbaum, R. TNFerade Biologic: preclinical toxicology of a novel adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene. Cancer Gene Ther. 2002, 9, 951-957.
70. Wei, D.; Dai, B.; Chen, S. Tumor targeted expression of adenovirus mediated CDglyTK gene regulated by irradiation via Egr-1 promoter Zhonghua. Yi. Xue. Za. Zhi. 2001, 81, 999-1003.
71. Hemminki, A.; Alvarez. R. D. Adenoviruses in oncology:a viable option? Biodrugs 16, 77-87.
72. Shayakhmetov, D. M.; Li, Z. Y.; Ni, S.; Lieber, A.Targeting of adenovirus vectors to tumor cells does not enable efficient transduction of breast cancer metastases. Cancer Res. 2002, 62, 1063-1068.
73. Blackwell, J. L.; Miller, C. R.; Douglas, J. T.; Li, H.; Reynolds, P. N.; Carroll, W. R.; Peters, G. E.; Strong, T. V.; Curiel, D. T. Retargeting to EGFR enhances adenovirus infection efficiency of squamous cell carcinoma. Arch. Otolaryngol. Head Neck Surg. 1999, 125, 856-863.
74. Dmitriev, I.; Kashentseva, E.; Rogers, B. E.; Krasnykh, V.; Curiel, D. T. Ectodomain of coxsackievirus and adenovirus receptor genetically fused to epidermal growth factor mediates adenovirus targeting to epidermal growth factor receptor-positive cells. J. Virol. 2000, 74, 6875-6884.
75. Haisma, H. J.; Pinedo, H. M.; Rijswijk, A.; der Meulen-Muileman, I.; Sosnowski, B. A.; Ying, W.; Beusechem, V. W.; Tillman, B. W.; Gerritsen, W. R.; Curiel, D. T. Tumor-specific gene transfer via an adenoviral vector targeted to the pan-carcinoma antigen EpCAM. Gene Ther. 1999, 6, 1469-1474.
76. Goldman, C. K.; Rogers, B. E.; Douglas, J. T.; Sosnowski, B. A.; Ying, W.; Siegal, G. P.; Baird, A.; Campain, J. A.; Curiel, D. T. Targeted gene delivery to Kaposi's sarcoma cells via the fibroblast growth factor receptor. Cancer Res. 1997, 57, 1447-1451.
77. Sonveaux, P.; Dessy, C.; Brouet, A.; Jordan, B. F.; Gregoire, V.; Gallez, B.; Balligand, J. L.; Feron, O.; Modulation of the tumor vasculature functionality by ionizing radiation accounts for tumor radiosensitization and promotes gene delivery. FASEB J. 2002, 16, 1979-1981.
78. Lu, W.; Li, S.; An, P.; Yu, B. Enhancement of ionizing radiation on liposome-mediated gene delivery in human rectal cancer HR-8348 cells. Zhonghua. Wai. Ke. Za. Zhi. 2002, 40, 604-605.
79. Stevens, C. W.; Puppi, M.; Cerniglia, G. J. Time-dose relationships in radiation-enhanced integration. Int. J. Radiat. Biol. 2001, 77, 841-846.
80. Toth, K.; Tarakanova, V.; Doronin, K.; Ward, P.; Kuppuswamy, M.;, Locke, J. E.; Dawson, J. E.; Kim, H. J.; Wold, W. S. Radiation increases the activity of oncolytic adenovirus cancer gene therapy vectors that overexpress the ADP (E3-11.6K) protein. Cancer Gene Ther. 2003, 10, 193-200.
81. Friedman, E. J. Immune modulation by ionizing radiation and its implications for cancer immunotherapy. Curr. Pharm. Des. 2002, 8, 1765-1780.
82. Matzinger, P. Tolerance, danger, and the extended family. Annu. Rev. Immunol. 1994, 12, 991-1045.
83. Matzinger, P. An innate sense of danger. Ann. N. Y. Acad. Sci. 2002, 961, 341-2.
84. Takamiya, Y.; Short, M. P.; Ezzeddine, Z. D.; Moolten, F. L.; Breakefield, X. O.; Martuza, R. L. Gene therapy of malignant brain tumors: a rat glioma line bearing the herpes simplex virus type 1-thymidine kinase gene and wild type retrovirus kills other tumor cells. J. Neurosci. Res. 1992, 33, 493-503.
85. Unger, M. M.; Wahl, J.; Ushmorov, A.; Buechele, B.; Simmet, T.; Debatin, K. M.; Beltinger, C. Enriching suicide gene bearing tumor cells for an increased bystander effect. Cancer Gene Ther. 2007, 14(1), 30-38.
86. Moolten, F. L.; Wells. J. M. Curability of tumors bearing herpes thymidine kinase genes transferred by retroviral vectors. J. Natl. Cancer Inst. 1990, 82, 297-300.
87. Culver, K. W.; Ram, Z.; Wallbridge, S.; Ishii, H.; Oldfield, E. H.; Blaese, R. M. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 1992, 256, 1550-1552.
88. Moolten, F. l. Drug sensitivity ('suicide') genes for selective cancer chemotherapy. Cancer Gene Ther. 1994, 1, 279-287.
89. Kim, J. H.; Kim, S. H.; Brown, S. L.; Freytag, S. O. Selective enhancement by an antiviral agent of the radiation-induced cell killing of human glioma cells transduced with HSV-tk gene. Cancer Res. 1994, 54, 6053-6056.
90. Van Dillen, I. J.; Mulder, N. H.; Vaalburg, W.; de Vries, E. F.; Hospers. G. A. Influence of the bystander effect on HSV-tk/GCV gene therapy. A review. Curr. Gene Ther. 2002, 2, 307-322.
91. rd; Wheeler, T.; Thompson, T. C.; Butler, E. B. Combining radiotherapy with gene therapy (from the bench to the bedside): a novel treatment strategy for prostate Cancer. Oncologist 2002, 7, 458-466.
92. Vlachaki, M. T.; Chhikara, M.; Aguilar, L.; Zhu, X.; Chiu, K. J.; Woo, S.; The, B. S.; Thompson, T. C, Butler, E. B.; Aguilar-Cordova, E. Enhanced therapeutic effect of multiple injections of HSV-TK + GCV gene therapy in combination with ionizing radiation in a mouse mammary tumor model. Int. J. Radiat. Oncol. Biol. Phys. 2001, 51, 1008-1017.
93. Chhikara, M.; Huang, H.; Vlachaki, M. T.; Zhu, X.; The, B.; Chiu, K. J.; Woo, S.; Berner, B.; Smith, E. O.; Oberg, K. C.; Aguilar, L. K.; Thompson, T. C.; Butler, E. B.; Aguilar-Cordova, E. Enhanced therapeutic effect of HSV-tk+GCV gene therapy and ionizing radiation for prostate cancer. Mol. Ther. 2001, 3, 536-542.
94. The, B. S.; Aguilar-Cordova, E.; Kernen, K.; Chou, C. C.; Shalev, M.; Vlachaki, M. T.; Miles, B.; Kadmon, D.; Mai, W. Y.; Caillouet, J.; Davis, M.; Ayala, G.; Wheeler, T.; Brady, J.; Carpenter, L. S.; Lu, H. H.; Chiu, J. K.; Woo, S. Y.; Thompson, T.; Butler, E. B. Phase I/II trial evaluating combined radiotherapy and in situ gene therapy with or without hormonal therapy in the treatment of prostate cancer - a preliminary report. Int. J. Radiat. Oncol. Biol. Phys. 2001, 51, 605-613.
95. The, B. S.; Ayala, G.; Aguilar, L.; Mai, W. Y.; Timme, T. L.; Vlachaki, M. T.; Miles, B.; Kadmon, D.; Wheeler, T.; Caillouet, J.; Davis, M.; Carpenter, L. S.; Lu, H. H.; Chiu, J. K.; Woo, S. Y.; Thompson, T.; Aguilar-Cordova, E.; Butler, E. B. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data. Int. J. Radiat. Oncol. Biol. Phys. 2004, 58, 1520-1529.
96. McGinn, C. J.; Shewach, D. S.; Lawrence, T. S. Radiosensitizing nucleosides. J. Natl. Cancer Inst. 1996, 88, 193-203.
97. Hwang, H. S.; Davis, T. W.; Houghton, J. A.; Kinsella, T. J. Radiosensitivity of thymidylate synthase-deficient human tumor cells is affected by progression through the G1 restriction point into S-phase: implications for fluoropyrimidine radiosensitization. Cancer Res. 2000, 60(1), 92-100.
98. Khil, M. S.; Kim, J. H.; Mullen, C. A.; Kim, S. H.; Freytag, S. O. Radiosensitization by 5-fluorocytosine of human colorectal carcinoma cells in culture transduced with cytosine deaminase gene. Clin. Cancer Res. 1996, 2(1), 53-57.
99. Gabel, M.; Kim, J. H.; Kolozsvary, A.; Khil, M.; Freytag, S. Selective in vivo radiosensitization by 5-fluorocytosine of human colorectal carcinoma cells transduced with the E. coli cytosine deaminase (CD) gene. Int. J. Radiat. Oncol. Biol. Phys. 1998, 41, 883-887.
100. Rogulski, K. R.; Kim, J. H.; Kim, S. H.; Freytag, S. O. Glioma cells transduced with an Escherichia coli CD/HSV-1 TK fusion gene exhibit enhanced metabolic suicide and radiosensitivity. Hum. Gene Ther. 1997, 8, 73-85.
101. Kim, J. H.; Kolozsvary, A.; Rogulski, K.; Khil, M. S.; Brown, S. L.; Freytag, S. O. Selective radiosensitization of 9L glioma in the brain transduced with double suicide fusion gene. Cancer J. Sci. Am. 1998, 4, 364-369.
102. Freytag, S. O.; Paielli, D.; Wing, M.; Rogulski, K.; Brown, S.; Kolozsvary, A.; Seely, J.; Barton, K.; Dragovic, A.; Kim, J. H. Efficacy and toxicity of replication-competent adenovirus-mediated double suicide gene therapy in combination with radiation therapy in an orthotopic mouse prostate cancer model. Int. J. Radiat. Oncol. Biol. Phys. 2002, 54, 873-885.
103. Boucher, P. D.; Im, M. M.; Freytag, S. O.; Shewach, D. S. A novel mechanism of synergistic cytotoxicity with 5-fluorocytosine and ganciclovir in double suicide gene therapy. Cancer Res. 2006, 66(6), 3230-3237
104. Freytag, S. O.; Stricke, H.; Pegg, J.; Paielli, D.; Pradhan, D. G.; Peabody, J.; DePeralta-Venturina, M.; Xia, X.; Brown, S.; Lu, M.; Kim, J. H. Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate- to high-risk prostate. Cancer Cancer Res. 2003, 63, 7497-7506.
105. Zagars, G. K.; Pollack, A. Kinetics of serum prostate specific antigen after external beam radiation for clinically localized prostate Cancer. Radiother. Oncol. 1997, 44, 213-221.
106. Freytag, S. O.; Khil, M.; Stricker, H.; Peabody, J.; Menon, M.; DePeralta-Venturina, M.; Nafziger, D.; Pegg, J.; Paielli, D.; Brown, S.; Barton, K.; Lu, M.; Aguilar-Cordova, E.; Kim, J. H. Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate Cancer. Cancer Res. 2002, 62, 4968-4976.
107. Riesco-Eizaguirre, G.; Santisteban, P. A perspective view of sodium iodide symporter research and its clinical implications. Eur. J. Endocrinol. 2006, 155(4), 495-512.
108. Mothersill, C.; Seymour, C. B. Radiation-induced bystander effects-implications for Cancer Nat. Rev Cancer 2004, 4, 158-164.
109. Nagasawa, H.; Little, J. B. Induction of sister chromatid exchanges by extremely low doses of alpha-particles. Cancer Res. 1992, 52, 6394-6396.
110. Lehnert, B. E.; Goodwin, E. H.; Deshpande, A. Extracellular factors following exposure to alpha particles can cause sister chromatid exchanges in normal human cells. Cancer Res. 1997, 57, 2164-2171.
111. Narayanan, P. K.; Goodwin, E. H.; Lehnert, B. E. Alpha particles initiate biological production of superoxide anions and hydrogen peroxide in human cells. Cancer Res. 1997, 57, 3963-3971.
112. Narayanan, P. K.; LaRue, K. E.; Goodwin, E. H.; Lehner, B. E. Alpha particles induce the production of interleukin-8 by human cells. Radiat. Res. 1999, 152, 57-63.
113. Little, J. B.; Azzam, E. I.; De Toledo, S. M.; Nagasawa, H. Bystander effects: intercellular transmission of radiation damage signals. Radiat. Prot. Dosimetry 2002, 99, 159-162.
114. Little, J. B. Genomic instability and bystander effects: a historical perspective. Oncogene 2003, 22, 6978-6987.
115. Mothersill, C.; Seymou, C. Low dose radiation effects: experimental haematology and the changing paradigm. Exp. Haematol. 2003, 31, 437-445.
116. Carrasco, N. Iodide transport in the thyroid gland. Biochem. Biophys. Acta 1993, 1154, 65-82.
117. Dai, G.; Levy, O.; Carrasco, N. Cloning and characterization of the thyroid iodide transporter. Nature. 1996, 379, 458-460.
118. Spitzweg, C.; Joba, W.; Eisenmenger, W.; Heufelder, A. E. Analysis of human sodium iodide symporter gene expression in extrathyroidal tissues and cloning of its complementary deoxyribonucleic acids from salivary gland, mammary gland, and gastric mucosa.. J. Clin. Endocrinol. Metab. 1998, 83, 1746-1751.
119. Jhiang, S. M.; Cho, J. Y.; Ryu, K. Y.; DeYoung, B. R.; Smanik, P. A.; McGaughy, V. R.; Fischer, A. H.; Mazzaferri, E. L. An immunohistochemical study of Na+/I- symporter in human thyroid tissues and salivary gland tissues. Endocrinology 1998, 139, 4416-4419.
120. Tazebay, U. H.; Wapnir, I. L.; Levy, O.; Dohan, O.; Zuckier, L. S.; Zhao, Q. H.; Deng, H. F.; Amenta, P. S.; Fineberg, S.; Pestell, R. G.; Carrasco, N. The mammary gland iodide transporter is expressed during lactation and in breast Cancer Nat. Med. 2000, 6, 871-878.
121. Smanik, P. A.; Ryu, K. Y.; Theil, K. S.; Mazzaferri, E. L.; Jhiang, S. M. Expression, exon-intron organization, and chromosome mapping of the human sodium iodide symporter. Endocrinology 1997, 138, 3555-3558.
122. Lazar, V.; Bidart, J. M.; Caillou, B.; Mahe, C.; Lacroix, L.; Filetti, S.; Schlumberger, M. Expression of the Na+/I- symporter gene in human thyroid tumors: a comparison study with other thyroid-specific genes. J. Clin. Endocrinol. Metab. 1999, 84(9), 3228-3234.
123. Cho, J. Y.; Leveille, R.; Kao, R.; Rousset, B.; Parlow, A. F.; Burak, W. E Jr.; Mazzaferri, E. L.; Jhiang, S. M. Hormonal regulation of radioiodide uptake activity and Na+/I- symporter expression in mammary glands. J. Clin. Endocrinol. Metab. 2000, 85, 2936-2943.
124. De La Vieja, A.; Dohan ,O.; Levy, O.; Carrasco, N. Molecular analysis of the sodium/iodide symporter: impact on thyroid and extrathyroid pathophysiology. Physiol Rev . 2000, 80, 1083-1105.
125. Dohan, O.; De la Vieja, A.; Paroder, V.; Riedel, C.; Artani, M.; Reed, M.; Ginter, C. S.; Carrasco, N. The sodium/iodide Symporter (NIS): characterization, regulation, and medical significance. Endocr. Rev. 2003, 24, 48-77.
126. Spitzweg, C.; O'Connor, M. K.; Bergert, E. R.; Tindall, D. J.; Young, C. Y.; Morris, J. C. Treatment of prostate cancer by radioiodine therapy after tissue-specific expression of the sodium iodide symporter. Cancer Res. 2000, 60, 6526-6530.
127. Spitzweg, C.; Dietz, A. B.; O'Connor, M. K.; Bergert, E. R.; Tindall, D. J.; Young, C. Y.; Morris, J. C. In vivo sodium iodide symporter gene therapy of prostate Cancer. Gene Ther. 2001, 8, 1524-1531.
128. Cho, J. Y.; Xing, S.; Liu, X.; Buckwalter, T. L.; Hwa, L, Sferra, T. J.; Chiu, I.; Jhiang, S. M. Expression and activity of human Na+/Isymporter in human glioma cells by adenovirus-mediated gene delivery. Gene Ther. 2000, 7, 740-749.
129. Gaut, A. W.; Niu, G.; Krager, K. J.; Graham, M. M.; Trask, D. K.; Domann, F. E. Genetically targeted radiotherapy of head and neck squamous cell carcinoma using the sodium-iodide symporter (NIS). Head & Neck 2004, 26, 265-271.
130. Dwyer, R. M.; Bergert, E. R.; O'Connor, M. K.; Gendler, S. J.; Morris, J. C. Adenovirus-mediated and targeted expression of the sodium-iodide symporter permits in vivo radioiodide imaging and therapy of pancreatic tumors. Hum. Gene Ther. 2006, 17(6), 661-668.
131. Spitzweg, C.; Morris, J. C. The sodium iodide symporter:its pathophysiological and therapeutic implications. Clin. Endocrinol. 2002, 57, 559-574.
132. Groot-Wassink, T.; Aboagye, E. O.; Glaser, M.; Lemoine, N. R.; Vassaux, G. Adenovirus biodistribution and noninvasive imaging of gene expression in vivo by positron emission tomography using human sodium/iodide symporter as reporter gene. Hum. Gene Ther. 2002, 13, 1723-1735.
133. Vassaux, G.; Groot-Wassink, T. In vivo Noninvasive Imaging for Gene Therapy. J. Biomed. Biotechnol. 2003, 2, 92-101.
134. Groot-Wassink, T.; Aboagye, E. O.; Wang, Y.; Lemoine, N. R.; Reader, A. J.; Vassaux, G. Quantitative imaging of Na/I symporter transgene expression using positron emission tomography in the living animal. Mol. Ther. 2004, 9, 436-442.
135. Groot-Wassink, T.; Aboagye, E. O.; Wang, Y.; Lemoine, N. R.; Keith, W. N.; Vassaux, G. Noninvasive imaging of the transcriptional activities of human telomerase promoter fragments in mice. Cancer Res. 2004, 64, 4906-4911.
136. 131I] iodobenzylguanidine. J. Nucl. Med. 1980, 21, 349-353.
137. 131I] meta-iodobenzylguanidine. Gene. Ther. 1999, 6, 1147-1152.
138. 131I] MIBG and clonogenic cell kill. Oncogene 2001, 20, 7804-7808.
139. 131I] metaiodobenzyl guanidine. J. Gene. Med. 2001, 3, 165-172.
140. Boyd, M.; Mairs, R. J.; Keith, W. N.; Ross, S. C.; Welsh, P.; Akabani, G.; Owens, J.; Vaidyanathan, G.; Carruthers, R.; Dorrens, J.; Zalutsky, M. R. An efficient targeted radiotherapy/gene therapy strategy utilising human telomerase promoters and radioastatine and harnessing radiationmediated bystander effects. J. Gene Med. 2004, 6, 937-947.
141. Williams, J. R.; Zhang, Y. G.; Dillehay, L. E. Sensitization processes in human tumor cells during protracted irradiation: possible exploitation in the clinic. Int. J. Radiat. Oncol. Biol. Phys. 1992, 24, 699-704.
142. Evan, G.; Littlewood, T. A matter of life and death. Science 1998, 281, 1317-1322.
143. Chene, P. Targeting p53 in Cancer. Curr. Med. Chem. Anti-Cancer Agents 2001, 1, 151-161.
144. Roth, J. A.; Grammer, S. F.; Swisher, S. G.; Komaki, R.; Nemunaitis, J.; Merritt, J.; Meyn, R. E. P53 gene replacement for cancer - interactions with DNA damaging agents. Acta. Oncol. 2001, 40, 739-744.
145. Lebedeva, I. V.; Su, Z. Z.; Sarkar, D.; Fisher, P. B. Restoring apoptosis as a strategy for cancer gene therapy: focus on p53 and mda-7. Semin. Cancer Biol. 2003, 13, 169-178.
146. Thor, A. D.; Moore, D. H. II.; Edgerton, S. M.; Kawasaki, E. S.; Reihsaus, E.; Lynch, H. T.; Marcus, J. N.; Schwartz, L.; Chen, L. C.; Mayall, B. H.; Smith, H. S. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J. Natl. Cancer Inst. 1992, 84, 845-855.
147. Hamada, M.; Fujiwara, T.; Hizuta, A.; Gochi, A.; Naomoto, Y.; Takakura, N.; Takahashi, K.; Roth, J. A.; Tanaka, N.; Orita, K. The p53 gene is a potent determinant of chemosensitivity and radiosensitivity in gastric and colorectal cancers. J. Cancer Res. Clin. Oncol. 1996, 122, 360-365.
148. Brachman, D. G.; Beckett, M.; Graves, D.; Haraf, D.; Vokes, E.; Weichselbaum, R. R. p53 mutation does not correlate with radiosensitivity in 24 head and neck cancer cell lines. Cancer Res. 1993, 53, 3667-3669.
149. Gallardo, D.; Drazan, K. E.; McBride, W. H. Adenovirus-based transfer of wild-type p53 gene increases ovarian tumor radiosensitivity. Cancer Res. 1996, 56, 4891-4893.
150. Badie, B.; Goh, C. S.; Klaver, J.; Herweijer, H.; Boothman, D. A. Combined radiation and p53 gene therapy of malignant glioma cells. Cancer Gene Ther. 1999, 6, 155-162.
151. Nishizaki, M.; Fujiwara, T.; Tanida, T.; Hizuta, A.; Nishimori, H.; Tokino, T.; Nakamura, Y.; Bouvetm M.; Roth, J. A.; Tanaka, N. Recombinant adenovirus expressing wild-type p53 is antiangiogenic: a proposed mechanism for bystander effect. Clin. Cancer Res. 1999, 5, 1015-1023.
152. Bouvet, M.; Bold, R. J.; Lee, J.; Evans, D.; Abbruzzese, J. L.; Chiao, P. J.; McConkey, D. J.; Chandra, J.; Chada, S.; Fang, B.; Roth, J. A. Adenovirus-mediated wild-type p53 tumor suppressor gene therapy induces apoptosis and suppresses growth of human pancreatic cancer. Ann. Surg. Oncol. 1998, 5, 681-688.
153. Fujiwara, T.; Grimm, E. A.; Mukhopadhyay, T.; Cai, D. W.; Owen-Schaub, L. B.; Roth, J. A. A retroviral wild-type p53 expression vector penetrates human lung cancer spheroids and inhibits growth by inducing apoptosis. Cancer Res. 1993, 53, 4129-4133.
154. Roth, J. A.; Grammer, S. F. Gene replacement therapy for non-small cell lung cancer: a review. Hematol. Oncol. Clin. North Am. 2004, 18, 215-229.
155. Huang, Q.; Pu, P.; Xia, Z.; You, Y. Exogenous wt-p53 enhances the antitumor effect of HSV-TK/GCV on C6 glioma cells. J. Neurooncol. 2006, Nov 11; [Epub ahead of print].
156. Wakasa, T.; Inoue T.; Kawai, N.; Murakami, J.; Kishi, K.; Fukui, K. The combination of ionizing radiation and expression of a wild type p53 gene via recombinant adenovirus induced a prominent tumour suppressing effect in human oral squamous cell carcinoma. Br. J. Radiol. 2002, 75, 657-662.
157. Spitz, F. R.; Nguyen, D.; Skibber, J. M.; Meyn, R. E.; Cristiano, R. J.; Roth, J. A. Adenoviral-mediated wild-type p53 gene expression sensitizes colorectal cancer cells to ionizing radiation. Clin. Cancer Res. 1996, 2, 1665-1671.
158. Sasaki, R.; Shirakawa, T.; Zhang, Z. J,etal. Additional gene therapy with Ad5CMV-p53 enhanced the efficacy of radiotherapy in human prostate cancer cells. Int. J. Radiat. Oncol. Biol. Phys. 2001, 51, 1336-1345.
159. Kim, I. A.; Yang, Y. J.; Yoon, S. C.; Choi, I. B.; Kay, C. S.; Kwon, H. C.; Kim, C. M.; Joe. Y. A.; Kang, J. K.; Hong, Y. K. Potential of adenoviral p53 gene therapy and irradiation for the treatment of malignant gliomas. Int. J. Oncol. 2001, 19, 1041-1047.
160. Gridley, D. S.; Andres, M. L.; Li, J.; Timiryasova, T.; Chen, B.; Fodor, I. Evaluation of radiation effects against C6 glioma in combination with vaccinia virus-p53 gene therapy. Int. J. Oncol. 1998, 13, 1093-1098.
161. Timiryasova, T. M.; Gridley, D. S.; Chen, B.; Andres, M. L.; Dutta-Roy, R.; Miller, G.; Bayeta, E. J.; Fodor, I. Radiation enhances the anti-tumor effects of vaccinia-p53 gene therapy in glioma. Technol. Cancer Res. Treat. 2003, 2, 223-235.
162. Lathe, R.; Kieny, M. P.; Gerlinger, P.; Clertant, P.; Guizani, I.; Cuzin, F.; Chambon, P. Tumour prevention and rejection with recombinant vaccinia. Nature 1987, 326, 878-880.
163. Nemunaitis, J.; Swisher, S. G.; Timmons, T.; Connors, D.; Mack, M.; Doerksen, L.; Weill, D.; Wait, J.; Lawrence, D. D.; Kemp, B. L.; Fossella, F.; Glisson, B. S.; Hong, W. K.; Khuri, F. R.; Kurie, J. M.; Lee, J. J.; Lee, J. S.; Nguyen, D. M.; Nesbitt, J. C.; Perez-Soler, R.; Pisters, K. M.; Putnam, J. B.; Richli, W. R.; Shin, D. M.; Walsh, G. L.; Merritt, J.; Roth, J. Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer. J. Clin. Oncol . 2000, 18(3), 609-622.
164. Pagliaro, L. C.; Keyhani, A.; Williams, D.; Woods, D.; Liu, B.; Perrotte, P.; Slaton, J. W.; Merritt, J. A.; Grossman, H. B.; Dinney, C. P. Repeated intravesical instillations of an adenoviral vector in patients with locally advanced bladder cancer: a phase I study of p53 gene therapy. J. Clin. Oncol. 2003, 21, 2247-2253.
165. Lang, F. F.; Bruner, J. M.; Fuller, G. N.; Aldape, K.; Prados, M. D.; Chang, S.; Berger, M. S.; McDermott, M. W.; Kunwar, S. M.; Junck, L. R.; Chandler, W.; Zwiebel, J. A.; Kaplan, R. S.; Yung, W. K. Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results. J. Clin. Oncol. 2003, 21, 2508-2518.
166. Weill, D.; Mack, M.; Roth, J.; Swisher, S.; Proksch, S.; Merritt, J.; Nemunaitis, J. Adenoviral-mediated p53 gene transfer to non-small cell lung cancer through endobronchial injection. Chest 2000, 118, 966-970.
167. Clayman, G. L.; El-Naggar, A. K.; Lippman, S. M.; Henderson, Y. C.; Frederick, M.; Merritt, J. A.; Zumstein, L. A.; Timmons, T. M.; Liu, T. J.; Ginsberg, L.; Roth, J. A.; Hong, W. K.; Bruso, P.; Goepfert, H. Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma. J. Clin. Oncol. 1998, 16(6), 2221-2232.
168. Swisher, S. G.; Roth, J. A.; Nemunaitis, J.; Lawrence, D. D.; Kemp, B. L.; Carrasco, C. H.; Connors, D. G.; El-Naggar, A. K.; Fossella, F.; Glisson, B. S.; Hong, W. K.; Khuri, F. R.; Kurie, J. M.; Lee, J. J.; Lee, J. S.; Mack, M.; Merritt, J. A.; Nguyen, D. M.; Nesbitt, J. C.; Perez-Soler, R.; Pisters, K. M.; Putnam, J. B. Jr.; Richli, W. R.; Savin, M.; Schrump, D. S.; Shin, D. M.; Shulkin, A.; Walsh, G. L.; Wait, J.; Weill, D.; Waugh, M. K. Adenovirus-mediated p53 gene transfer in advanced nonsmall-cell lung cancer. J. Natl. Cancer Inst. 1999, 91, 763-771.
169. Swisher, S. G.; Roth, J. A.; Komaki, R.; Gu, J.; Lee, J. J.; Hicks, M.; Ro, J. Y.; Hong, W. K.; Merritt, J. A, Ahrar, K.; Atkinson, N. E.; Correa, A. M.; Dolormente, M.; Dreiling, L.; El-Naggar, A. K.; Fossella, F.; Francisco, R.; Glisson, B.; Grammer, S.; Herbst, R.; Huaringa, A.; Kemp, B.; Khuri, F. R.; Kurie, J. M.; Liao, Z.; McDonnell, T. J.; Morice, R.; Morello, F.; Munden, R.; Papadimitrakopoulou, V.; Pisters, K. M.; Putnam, J. B. Jr.; Sarabia, A. J.; Shelton, T.; Stevens, C.; Shin, D. M.; Smythe, W. R.; Vaporciyan, A. A.; Walsh, G. L.; Yin. Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy. Clin. Cancer Res. 2003, 9, 93-101.
170. Naumann, U.; Kugler, S.; Wolburg, H.; Wick, W.; Rascher, G.; Schulz, J. B.; Conseiller, E.; Bahr, M.; Weller, M. Chimeric tumor suppressor 1, a p53-derived chimeric tumor suppressor gene, kills p53 mutant and p53 wild-type glioma cells in synergy with irradiation and CD95 ligand. Cancer Res. 2001, 61, 5833-5842.
171. Norris, J. S.; Hyer, M. L.; Voelkel-Johnson, C.; Lowe, S. L.; Rubinchik, S.; Dong, J. Y. The use of Fas Ligand, TRAIL and Bax in gene therapy of prostate cancer. Curr. Gene Ther. 2001, 1, 123-136.
172. Kagawa, S.; Gu, J.; Swisher, S. G.; Ji, L.; Roth, J. A.; Lai, D.; Stephens, L. C.; Fang, B. Antitumor effect of adenovirus-mediated Bax gene transfer on p53-sensitive and p53-resistant cancer lines. Cancer Res. 2000, 60, 1157-1161.
173. Arafat, W. O.; Buchsbaum, D. J.; Gomez-Navarro, J.; Tawil, S. A.; Olsen C, Xiang, J.; El-Akad, H.; Salama, A. M.; Badib, A. O.; Stackhouse, M. A.; Curiel, D. T. An adenovirus encoding proapoptotic Bax synergistically radiosensitizes malignant glioma. Int. J. Radiat. Oncol. Biol. Phys. 2003, 55, 1037-1050.
174. Arafat, W. O.; Gomez-Navarro, J.; Xiang, J.; Barnes, M. N.; Mahasreshti, P.; Alvarez, R. D.; Siegal, G. P.; Badib, A. O.; Buchsbaum, D.; Curiel, D. T.; Stackhouse, M. A. An adenovirus encoding proapoptotic Bax induces apoptosis and enhances the radiation effect in human ovarian Cancer. Mol. Ther. 2000, 1, 545-554.
175. Su, Z. Z.; Lebedeva, I. V.; Sarkar, D.; Gopalkrishnan, R. V.; Sauane, M.; Sigmon, C.; Yacoub, A.; Valerie, K.; Dent, P.; Fisher, P. B. Melanoma differentiation associated gene-7, mda-7/IL-24, selectively induces growth suppression, apoptosis and radiosensitization in malignant gliomas in a p53-independent manner. Oncogene 2003, 22, 1164-1180.
176. Shankar, S.; Singh, T. R.; Chen, X.; Thakkar, H.; Firnin, J.; Srivastava, R. K. The sequential treatment with ionizing radiation followed by TRAIL/Apo-2L reduces tumor growth and induces apoptosis of breast tumor xenografts in nude mice. Int. J. Oncol. 2004, 24, 1133-1140.
177. Shankar, S.; Srivastava, R. K. Enhancement of therapeutic potential of TRAIL by cancer chemotherapy and irradiation: mechanisms and clinical implications. Drug Resist. Update 2004, 7, 139-156.
178. Marini, P.; Schmid, A.; Jendrossek, V.; Faltin. H.; Daniel, P. T.; Budach, W.; Belka, C. Irradiation specifically sensitises solid tumour cell lines to TRAIL mediated apoptosis. BMC. Cancer 2005, 5, 5.
179. Chinnaiyan, A. M.; Prasad, U.; Shankar, S.; Hamstra, D.; A, Shanaiah, M.; Chenevert, T. L.; Ross. B. D.; Rehemtulla. Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy. Proc. Natl. Acad. Sci. USA 2000, 7, 1754-1759.
180. Berek, J. S.; Schultes, B. C.; Nicodemus, C. F. Biologic and immunologic therapies for ovarian Cancer. J. Clin. Oncol. 2003, 21, 168-174.
181. Ribas, A.; Glaspy, J. A.; Lee, Y.; Dissette, V. B.; Seja, E.; Vu, H. T.; Tchekmedyian, N. S.; Oseguera, D.; Comin-Anduix, B.; Wargo, J. A.; Amarnani, S. N.; McBride, W. H.; Economou, J. S.; Butterfield, L. H. Role of dendritic cell phenotype, determinant spreading, and negative costimulatory blockade in dendritic cell-based melanoma immunotherapy. J. Immunother. 2004, 27, 354-367.
182. Tirapu, I.; Rodriguez-Calvillo, M.; Qian, C.; Duarte, M.; Smerdou, C.; Palencia, B.; Mazzolini, G.; Prieto, J.; Melero, I. Cytokine gene transfer into dendritic cells for cancer treatment. Curr. Gene Ther. 2002, 2, 79-89.
183. Melcher, A.; Gough, M.; Todryk, S.; Vile, R. Apoptosis or necrosis for tumor immunotherapy: what's in a name? J. Mol. Med. 1999, 77, 824-833.
184. Ferrari, S.; Griesenbach, U.; Geddes, D. M.; Alton, E. Immunological hurdles to lung gene therapy. Clin. Exp. Immunol. 2003, 132, 1-8.
185. Friedman, E. J. Immune modulation by ionizing radiation and its implications for cancer immunotherapy. Curr. Pharm. Des. 2002, 8, 1765-1780.
186. Demaria, S.; Bhardwaj, N.; McBride, W. H.; Formenti, S. C. Combining radiotherapy and immunotherapy: a revived partnership. Int. J. Radiat. Oncol. Biol. Phys. 2005, 63(3), 655-666.
187. Li, S.; Lu, W.; An, P.; Yu, B. Three-pronged approach to treat rectal cancer: liposome transfer cytosine deaminase gene, ionizing radiation and dendritic cells. Zhonghua. Wai. Ke. Za. Zhi. 2002, 40, 274-6.
188. Nishitani, M. A.; Sakai, T.; Ishii, K.; Zhang, M.; Nakano, Y.; Nitta, Y.; Miyazaki, J.; Kanayama, H. O.; Kagawa, S.; Himeno, K. A convenient cancer vaccine therapy with in vivo transfer of interleukin 12 expression plasmid using gene gun technology after priming with irradiated carcinoma cells. Cancer Gene Ther. 2002, 9, 156-163.
189. Gridley, D. S.; Andres, M. L.; Garner, C.; Mao, X. W.; Slater, J. M. Evaluation of TNF-alpha effects on radiation efficacy in a human lung adenocarcinoma model. Oncol. Res. 1996, 8, 485-495.
190. Gridley, D. S.; Archambeau, J. O.; Andres, M. A.; Mao, X. W.; Wright, K.; Slater, J. M. Tumor necrosis factor-alpha enhances antitumor effects of radiation against glioma xenografts. Oncol. Res. 1997, 9, 217-227.
191. Mezhir, J. J.; Smith, K. D.; Posner, M. C.; Senzer, N.; Yamini, B.; Kufe, D. W.; Weichselbaum, R. R. Ionizing radiation: a genetic switch for cancer therapy. Cancer Gene Ther. 2006, 13(1), 1-6.
192. Li, J.; Andres, M. L.; Fodor, I.; Nelson, G. A.; Gridley, D. S. Evaluation of pGL1-TNF-alpha therapy in combination with radiation. Oncol. Res. 1998, 10, 379-387.
193. Gridley, D. S.; Timiryasova, T. M.; Miller, G. M.; Andres, M. L.; Dutta-Roy, R.; Bayeta, E. J.; Fodor, I. Evaluation of TNF-alpha/Bax gene therapy and radiation against C6 glioma xenografts. Technol. Cancer Res. Treat. 2003, 2, 41-50.
194. rd; Kufe, D. W. Recombinant human tumor necrosis factor administered as a 24-hour intravenous infusion. A phase I and pharmacologic study. J. Natl. Cancer Inst. 1988, 80, 1039-1044.
195. ]195] Feinberg, B.; Kurzrock, R.; Talpaz, M.; Blick, M.; Saks, S.; Gutterman, J. U. A phase I trial of intravenously-administered recombinant tumor necrosis factor-alpha in cancer patients. J. Clin. Oncol. 1988, 6, 1328-1234.
196. Hallahan, D. E.; Vokes, E. E.; Rubin, S. J.; O'Brien, S.; Samuels, B.; Vijaykumar, S.; Kufe, D. W, Phillips, R.; Weichselbaum, R. R. Phase I Dose-Escalation Study of Tumor Necrosis Factor-alpha and Concomitant Radiation Therapy. Cancer J. Sci. Am. 1995, 1, 204.
197. Chung, T. D.; Mauceri, H. J.; Hallahan, D. E.; Yu, J. J.; Chung, S.; Grdina, W. L.; Yajnik, S.; Kufe, D. W.; Weichselbaum R.R. Tumor necrosis factor-alpha-based gene therapy enhances radiation cytotoxicity in human prostate Cancer. Cancer Gene Ther. 1998, 5, 344-349.
198. Staba, M. J.; Mauceri, H. J.; Kufe, D. W.; Hallahan, D. E.; Weichselbaum, R. R. Adenoviral TNF-alpha gene therapy and radiation damage tumor vasculature in a human malignant glioma xenograft. Gene Ther. 1998, 5, 293-300.
199. Senzer, N.; Mani, S.; Rosemurgy, A.; Nemunaitis, J.; Cunningham, C.; Guha, C.; Bayol, N.; Gillen, M.; Chu, K.; Rasmussen, C.; Rasmussen, H.; Kufe, D.; Weichselbaum, R.; Hanna, N. TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: a phase I study in patients with solid tumors. J. Clin. Oncol. 2004, 22, 592-601.
200. Mundt, A. J.; Vijayakumar, S.; Nemunaitis, J.; Sandler, A.; Schwartz, H.; Hanna, N.; Peabody, T.; Senzer, N.; Chu, K.; Rasmussen, C. S.; Kessler, P. D.; Rasmussen, H. S.; Warso, M.; Kufe, D. W.; Gupta, T. D.; Weichselbaum, R. R. A Phase I trial of TNFerade biologic in patients with soft tissue sarcoma in the extremities. Clin. Cancer Res. 2004, 10, 5747-5753.
201. Gorski, D. H.; Beckett, M. A.; Jaskowiak, N. T.; Calvin, D. P.; Mauceri, H. J.; Salloum, R. M.; Seetharam, S.;, Koons, A.; Hari, D. M.; Kufe, D. W.; Weichselbaum, R. R. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res. 1999, 15, 59, 3374-3378.
202. Horsman, M. R, Murata, R. Combination of vascular targeting agents with thermal or radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 2002, 54, 1518-1523.
203. Koukourakis, M. I. Tumour angiogenesis and response to radiotherapy. Anti Cancer Res. 2001, 2, 4285-4300.
204. Jain, R. K. Normalizing tumour vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat. Med. 2001, 7, 987-989.
205. Geng, L.; Donnelly, E.; McMahon, G.; Lin, P. C.; Sierra-Rivera, E.; Oshinka, H.; Hallahan, D. E. Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy. Cancer Res. 2001, 61, 2413-2419.
206. Fukumura, D.; Jain, R. K. Tumor microenvironment abnormalities: Causes, consequences, and strategies to normalize. J. Cell. Biochem. 2006, Dec 14, [Epub ahead of print].
207. Blezinger, P.; Wang, J.; Gondo, M.; Quezada, A.; Mehrens, D.; French, M.; Singhal.; A, Sullivan, S.; Rolland, A.; Ralston, R.; Min, W. Systemic inhibition of tumor growth and tumor metastases by intramuscular administration of the endostatin gene. Nat. Biotechnol. 1999, 17, 343-348.
208. O'Reilly, M. S.; Boehm, T.; Shing, Y.; Fukai, N.; Vasios, G.; Lane, W. S.; Flynn, E.; Birkhead, J. R.; Olsen, B. R.; Folkman, J. Endostatin: an endogenous inhibitor of angiogenesis and tumour growth. Cell 1997, 88, 277-285.
209. Hanna, N. N.; Seetharam, S.; Mauceri, H. J.; Beckett, M. A.; Jaskowiak, N. T.; Salloum, R. M.; Hari, D.; Dhanabal, M.; Ramchandran, R.; Kalluri, R.; Sukhatme, V. P.; Kufe, D. W.; Weichselbaum, R. R. Antitumor interaction of short-course endostatin and ionizing radiation. Cancer J. 2000, 6, 287-293.
210. Shi, W.; Teschendorf, C.; Muzyczka, N.; Siemann, D.W. Gene therapy delivery of endostatin enhances the treatment efficacy of radiation. Radiother. Oncol. 2003, 66, 1-9.
211. Luo, X.; Andres, M. L.; Timiryasova, T. M.; Fodor, I.; Slater, J. M.; Gridley, D. S. Radiation-enhanced endostatin gene expression and effects of combination treatment. Technol. Cancer Res. Treat. 2005, 4, 193-202.
212. Worthington, J.; Robson, T.; O'Keeffe, M.; Hirst, D. G. Tumour cell radiosensitization using constitutive (CMV) and radiation inducible (WAF1) promoters to drive the iNOS gene: a novel suicide gene therapy. Gene. Ther. 2002, 9, 263-269.
213. Shiloh, Y. ATM and ATR: Networking cellular responses to DNA damage. Curr. Opin. Genet. dev. 2001, 11, 71-77.
214. Sanchez-Perez, I. DNA repair inhibitors in cancer treatment. Clin. Transl. Oncol. 2006, 8(9), 642-646.
215. Trofimova, I.; Dimtchev, A.; Jung, M.; Rosenthal, D.; Smulson, M.; Dritschilo, A.; Soldatenkov, V. Gene therapy for prostate cancer by targeting poly(ADP-ribose) polymerase. Cancer Res. 2002, 62, 6879-6883
216. Marangoni, E.; Le Romancer, M.; Foray, N.; Muller, C.; Douc-Rasy, S.; Vaganay, S.; Abdulkarim, B.; Barrois, M.; Calsou, P.; Bernier, J.; Salles, B.; Bourhis, J. Transfer of Ku86 RNA antisense decreases the radioresistance of human fibroblasts. Cancer Gene Ther. 2000, 7, 339-346.
217. Li, G. C.; He, F.; Shao, X.; Urano, M.; Shen, L.; Kim, D.; Borrelli, M.; Leibel, SA.; Gutin, P. H.; Ling, C. C. Adenovirus-mediated heatactivated antisense Ku70 expression radiosensitizes tumor cells in vitro and in vivo. Cancer Res. 2003, 63, 3268-3274.
218. Collis, S. J.; Swartz, M. J.; Nelson, W. G.; DeWeese, T. L. Enhanced radiation and chemotherapy-mediated cell killing of human cancer cells by small inhibitory RNA silencing of DNA repair factors. Cancer Res. 2003, 63, 1550-1554.
219. Collis, S. J.; Ketner, G. W.; Hicks, J. L.; Nelson, W. G.; Demarzo, A. M.; Deweese, T. L. Expression of the DNA-PK binding protein E4-34K fails to confer radiation sensitivity to mammalian cells. Int. J. Radiat. Biol. 2003, 79, 53-60.
220. Ruan, H.; Deen, D. F. Use of hypoxia-regulated gene expression in tumor-specific gene therapy. Curr. Opin. Investig. Drugs 2001, 2, 839-843.
221. Salloum, R. M.; Saunders, M. P.; Mauceri, H. J.; Hanna, N. N.; Gorski, D. H.; Posner, M. C.; Stratford, I. J.; Weichselbaum, R. R. Dual induction of the Epo-Egr-TNF-alpha- plasmid in hypoxic human colon adenocarcinoma produces tumor growth delay. Am. Surg. 2003, 69, 24-27.
222. Patterson, A. V.; Williams, K. J.; Cowen, R. L.; Jaffar, M.; Telfer, B. A.; Saunders, M.; Airley, R.; Honess, D.; van der Kogel, A. J.; Wolf, C. R.; Stratford, I. J. Oxygen-sensitive enzyme-prodrug gene therapy for the eradication of radiation-resistant solid tumours. Gene Ther. 2002, 9, 946-954.
223. Ford, A. C.; Grandis, J. R. Targeting epidermal growth factor receptor in head and neck Cancer. Head Neck 2003, 25, 67-73.
224. Schmidt-Ullrich, R. K.; Valerie, K. C.; Chan, W.; McWilliams, D. Altered expression of epidermal growth factor receptor and estrogen receptor in MCF-7 cells after single and repeated radiation exposures. Int J. Radiat. Oncol. Biol. Phys. 1994, 29, 813-819.
225. Lammering, G.; Valerie, K.; Lin, P. S.; Hewit, T. H.; Schmidt-Ullrich, R. K. Radiation-induced activation of a common variant of EGFR confers enhanced radioresistance. Radiother. Oncol. 2004, 72, 267-273.
226. Burdak-Rothkamm, S.; Rube, C. E.; Nguyen, T. P.; Ludwig, D.; Feldmann, K.; Wiegel, T.; Rube, C. Radiosensitivity of Tumor Cell Lines after Pretreatment with the EGFR Tyrosine Kinase Inhibitor ZD1839 (Iressa((R)). Strahlenther. Onkol. 2005, 181, 197-204.
227. Bernier, J. Cetuximab in the treatment of head and neck Cancer Expert Rev. AntiCancer Ther. 2006, 6(11), 1539-1552.
228. Lammering, G.; Lin, P. S.; Contessa, J. N.; Hampton, J. L.; Valerie, K.; Schmidt-Ullrich, R. K. Adenovirus-mediated overexpression of dominant negative epidermal growth factor receptor-CD533 as a gene therapeutic approach radiosensitizes human carcinoma and malignant glioma cells. Int. J. Radiat. Oncol. Biol. Phys. 2001, 51, 775-784.
229. Lammering, G.; Hewit, T. H.; Hawkins, W. T.; Contessa, J. N.; Reardon, D. B.; Lin, P. S.; Valerie, K.; Dent, P.; Mikkelsen, R. B.; Schmidt-Ullrich, R. K. Epidermal growth factor receptor as a genetic therapy target for carcinoma cell radiosensitization. J. Natl. Cancer Ins. 2001, 93, 921-929
230. Lammering, G.; Hewit, T. H.; Holmes, M.; Valerie, K.; Hawkins, W.; Lin, P. S.; Mikkelsen, R. B.; Schmidt-Ullrich, R. K. Inhibition of the type III epidermal growth factor receptor variant mutant receptor by dominant-negative EGFR-CD533 enhances malignant glioma cell radiosensitivity. Cancer Res. 2004, 10, 6732-6743.
231. Soldatenkov, V. A.; Dritschilo, A.; Wang, F. H.; Olah, Z.; Anderson, W. B.; Kasid, U. Inhibition of Raf-1 protein kinase by antisense phosphorothioate oligodeoxyribonucleotide is associated with sensitization of human laryngeal squamous carcinoma cells to gamma radiation. Cancer J. Sci. Am. 1997, 3, 13-20.
232. Gokhale, P. C.; McRae, D.; Monia, B. P.; Bagg, A.; Rahman, A.; Dritschilo, A.; Kasid, U. Antisense raf oligodeoxyribonucleotide is a radiosensitizer in vivo. Antisense Nucleic Acid Drug Dev. 1999, 9, 191-201.
233. Pajonk, F.; Pajonk, K.; McBride, W. H. Inhibition of NF-kappaB, clonogenicity, and radiosensitivity of human cancer cells. J. Natl. Cancer Inst. 1999, 91, 1956-1960
234. Mukogawa, T.; Koyama, F.; Tachibana, M.; Takayanagi, A.; Shimizu, N.; Fujii, H.; Ueno, M.; Matsumoto, H.; Takeuchi, T.; Nakajima, Y. Adenovirus-mediated gene transduction of truncated I kappa B alpha enhances radiosensitivity in human colon cancer cells. Cancer Sci. 2003, 94, 745-750.
235. Woo, Y.; Adusumilli, P. S.; Fong, Y. Advances in oncolytic viral therapy. Curr. Opin. Investig. Drugs 2006, 7(6), 549-559.
236. Marcato, P.; Shmulevitz, M.; Lee, P. W. Connecting reovirus oncolysis and Ras signaling. Cell Cycle 2005, 4, 556-559.
237. Rogulski, K. R.; Freytag, S. O.; Zhang, K.; Gilbert, J. D.; Paielli, D. L.; Kim, J. H.; Heise, C. C.; Kirn, D. H. In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy. Cancer Res. 2000, 60, 1193-1196.
238. Bischoff, J. R.; Kirn, D. H.; Williams, A.; etal.An adenovirus mutant that replicates selectively in p53 deficient tumour cells. Science (Was DC) 1996, 274, 373-376.
239. Hall, A. R.; Dix, B. R.; O'Carroll, S. J. p53 dependent cell death/apoptosis is required for a productive adenovirus infection Nat. Med. 1998, 4, 1068-1072.
240. Turnell, A. S.; Grand, R. J.; Gallimore, P. H. The replicative capacities of large E1B-null group A and group C adenoviruses are indepenedent of p53 status. J. Virol. 1999, 73, 2074-2083.
241. Geoerger, B.; Grill, J.; Opolon, P.; Morizet, J.; Aubert, G.; Lecluse, Y.; van Beusechem, V. W.; Gerritsen, W. R.; Kirn, D. H.; Vassal, G. Potentiation of radiation therapy by the oncolytic adenovirus dl1520 (ONYX-015) in human malignant glioma xenografts. Br. J. Cancer 2003, 89, 577-584.
242. Portella, G.; Pacelli, R.; Libertini, S.; Cella, L.; Vecchio, G.; Salvatore, M.; Fusco, A. ONYX-015 enhances radiation-induced death of human anaplastic thyroid carcinoma cells. J. Clin. Endocrinol. Metab. 2003, 88, 5027-5032.
243. Chen, Y.; DeWeese, T.; Dilley, J.; Zhang, Y.; Li, Y.; Ramesh, N.; Lee, J.; Pennathur-Das, R.; Radzyminski, J.; Wypych, J.; Brignetti, D.; Scott, S.; Stephens, J.; Karpf, D. B.; Henderson, D. R.; Yu, D. C. CV706, a prostate cancer-specific adenovirus variant, in combination with radiotherapy produces synergistic antitumor efficacy without increasing toxicity. Cancer Res. 2001, 61, 5453-5460.
244. Yu, D. C.; Chen, Y.; Seng, M.; Dilley, J.; Henderson, D. R. The addition of adenovirus type 5 region E3 enables calydon virus 787 to eliminate distant prostate tumor xenografts. Cancer Res. 1999, 59, 4200-4203.
245. Dilley, J.; Reddy, S.; Ko, D.; Nguyen, N.; Rojas, G.; Working, P.; Yu, D. C. Oncolytic adenovirus CG7870 in combination with radiation demonstrates synergistic enhancements of antitumor efficacy without loss of specificity. Cancer Gene Ther. 2005, 12, 715-722.
246. Lamfers, M. L.; Grill, J.; Dirven, C. M.; Van Beusechem, V. W.; Geoerger, B.; Van Den Berg, J.; Alemany, R.; Fueyo, J.; Curiel, D. T.; Vassal, G.; Pinedo, H. M.; Vandertop, W. P.; Gerritsen, W. R. Potential of the conditionally replicative adenovirus Ad5-Delta24RGD in the treatment of malignant gliomas and its enhanced effect with radiotherapy. Cancer Res. 2002, 62, 5736-5742.
247. Toth, K.; Tarakanova, V.; Doronin, K.; Ward, P.; Kuppuswamy, M.; Locke, J. E.; Dawson, J. E.; Kim, H. J.; Wold, W. S. Radiation increases the activity of oncolytic adenovirus cancer gene therapy vectors that overexpress the ADP (E3-11.6K) protein. Cancer Gene Ther. 2003, 10, 193-200.
248. Lin, E.; Nemunaitis, J. Oncolytic viral therapies. Cancer Gene Ther. 2004, 11, 643-644.
249. Kirn, D. Oncolytic virotherapy for cancer with the adenovirus dl1520 (Onyx-015): results of phase I and II trials. Expert Opin. Biol. Ther. 2001, 1, 525-538.
250. DeWeese, T. L.; van der Poel, H.; Li, S.; Mikhak B.; Drew, R.; Goemann, M.; Hamper, U.; DeJong, R.; Detorie, N.; Rodriguez, R.; Haulk, T.; DeMarzo, A. M.; Piantadosi, S.; Yu, D. C.; Chen, Y.; Henderson, D. R.; Carducci, M. A.; Nelson, W. G.; Simons, J. W. A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res. 2001, 61, 7464-7472.
251. Chu, R. L.; Post, D. E.; Khuri, F. R.; Van Meir, E. G. Use of replicating oncolytic adenoviruses in combination therapy for cancer. Clin. Cancer Res. 2004, 10, 5299-5312.
252. Shao, R.; Karunagaran, D.; Zhou, B. P.; Li, K.; Lo, S. S.; Deng, J.; Chiao, P.; Hung, M. C. Inhibition of nuclear factor-kappaB activity is involved in E1A-mediated sensitization of radiation-induced apoptosis. J. Biol. Chem. 1997, 272, 32739-32742.
253. Varghese, S.; Rabkin, S. D. Oncolytic herpes simplex virus vectors for cancer virotherapy. Cancer Gene Ther. 2002, 9, 967-978.
254. Toyoizumi, T.; Mick, R.; Abbas, A. E.; Kang, E. H.; Kaiser, L. R.; Molnar-Kimber, K. L. Combined therapy with chemotherapeutic agents and herpes simplex virus type 1 ICP34.5 mutant (HSV-1716) in human non-small cell lung Cancer. Hum. Gene Ther. 1999, 10, 3013-3029.
255. Advani, S. J.; Chung, S. M.; Yan, S. Y.; Gillespie, G. Y.; Markert, J. M, Whitley, R. J.; Roizman, B.; Weichselbaum, R. R. Replicationcompetent, nonneuroinvasive genetically engineered herpes virus is highly effective in the treatment of therapy-resistant experimental human tumors. Cancer Res. 1999, 59, 2055-2058.
256. Chung, S. M.; Advani, S. J.; Bradley, J. D.; Kataoka, Y.; Vashistha, K.; Yan, S. Y.; Markert, J. M.; Gillespie, G. Y.; Whitley, R. J.; Roizman, B.; Weichselbaum, R. R. The use of a genetically engineered herpes simplex virus (R7020) with ionizing radiation for experimental hepatoma. Gene. Ther. 2002, 9, 75-80.
257. Markert, J. M.; Medlock, M. D.; Rabkin, S. D.; Gillespie, G. Y.; Todo, T.; Hunter, W. D.; Palmer, C. A.; Feigenbaum, F.; Tornatore, C.; Tufaro, F.; Martuza, R. L. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther. 2000, 7, 867-74.
258. Rampling, R.; Cruickshank, G.; Papanastassiou, V.; Nicoll, J.; Hadley, D.; Brennan, D.; Petty, R.; MacLean, A.; Harland, J.; McKie, E.; Mabbs, R.; Brown, M. Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther. 2000, 7, 859-866.
259. MacKie, R. M.; Stewart, B.; Brown, S. M. Intralesional injection of herpes simplex virus 1716 in metastatic melanoma. Lancet 2001, 17, 525-526.
260. Hu, J.; McNeish, I.; Shorrock, C.; et al. A phase1 clinical trial with Oncovex GMCSF. Mol. Ther. 2003, 7, S447.
261. Bennett, J. J.; Delman, K. A.; Burt, B. M.; Mariotti, A.; Malhotra, S.; Zager, J.; Petrowsky, H.; Mastorides, S.; Federoff, H.; Fong, Y. Comparison of safety, delivery, and efficacy of two oncolytic herpes viruses (G207 and NV1020) for peritoneal Cancer. Cancer Gene Ther. 2002, 9, 935-945.
262. Greenberger, J. S.; Epperly, M. W.; Gretton, J.; Jefferson, M.; Nie, S.; Bernarding, M.; Kagan, V.; Guo, H. L. Radioprotective gene therapy. Curr. Gene Ther. 2003, 3, 183-195.
263. Jatoi, A.; Thomas, C. R. Jr. Esphageal cancer and the esophagus.; challenges and potential strategies for selective cytoprotection of the tumour bearing organ during cancer treatment. Semin. Radiat. Oncol. 2002, 12, 62-67.
264. Stewart, B. W.; Kliheus, P. The global burden of Cancer In: World cancer report. Geneva, Switzerland: World. Health Organization 2003, 12-19.
265. Blaese, R. M.; Culver, K. W.; Miller, A. D.; Carter, C. S.; Fleisher, T.; Clerici, M.; Shearer, G.; Chang, L.; Chiang, Y.; Tolstoshev, P.; Greenblatt, J. J.; Rosenberg, S. A.; Klein, H.; Berge, M.; Mullen, C. A.; Ramsey, W. J.; Muul, L.; Morgan, R. A.; Anderson, W. F. T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years. Science 1995, 270, 475-480.
266. Cavazzana-Calvo, M.; Hacein-Bey. S.; Yates, F.; de Villartay, J. P.; Le Deist, F.; Fischer, A. Gene therapy of severe combined immunodeficiencies. J. Gene Med. 2001, 3, 201-206.
267. Aiuti, A.; Slavin, S.; Aker, M.; Ficara, F.; Deola, S.; Mortellaro, A.; Morecki, S.; Andolfi, G.; Tabucchi, A.; Carlucci, F.; Marinello, E.; Cattaneo, F.; Vai, S.; Servida, P.; Miniero, R.; Roncarolo, M. G.; Bordignon, C. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 2002, 296, 2410-2413.
268. Winckler, T. A third tumor following SCID gene therapy. Pharm. Unserer. Zeit. 2005, 34, 184-185.
269. Bushman, F. Targeting retroviral integration. Mol. Ther. 2000, 6(5), 570-571.
270. Cavazzana- Calvo, M.; Thrasher, A.; Mavilio, F. The future of gene therapy. Nature 2004, 427, 779-781.